FermaVir Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

FermaVir Pharmaceuticals Ownership

Who owns FermaVir Pharmaceuticals?

FermaVir Pharmaceuticals is owned by Inhibitex. It was acquired on April 10, 2007.

FermaVir Pharmaceuticals Business Overview

Where is FermaVir Pharmaceuticals headquartered?

FermaVir Pharmaceuticals is headquartered in New York, New York.

What sector is FermaVir Pharmaceuticals in?

FermaVir Pharmaceuticals is a life science company.

Life Science M&A Summary in 2007

Out of 60 sectors in the Mergr database, life science ranked 10 in number of deals in 2007. The largest life science acquisition in 2007 was Organon BioSciences N.V. - which was acquired by Schering-Plough for $12.4B.

Join Mergr to view all 131 acquisitions of life science companies in 2007, including 29 acquisitions by private equity firms, and 102 by strategics.

FermaVir Pharmaceuticals, Inc.

420 Lexington Avenue Suite 445,
New York, New York 10170
United States,
www.fermavir.com

FermaVir Pharmaceuticals, Inc. is a biotechnology company that develops antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. FermaVir’s Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is FV-100, a potential breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster.


 Subscribe to unlock this and 206,651
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 199K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.